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Purpose: A non-synonymous single nucleotide polymorphism (SNP) in complement component 3 has been shown to
increase the risk of age-related macular degeneration (AMD). We assess its effect on AMD risk in a Northern Irish sample,
test for gene–gene and gene–environment interaction, and review a risk prediction model.
Methods: SNP rs2230199 was genotyped in 1,358 samples, which comprised 437 cases, 436 no-disease controls, and
485 participants randomly sampled from the Northern Ireland population. Allele frequencies were assessed in cases and
controls. Logistic regression analysis was used to assess interaction and develop a risk prediction model.
Results: We report a minor allele frequency of 0.248 for rs2230199 in the population (n=485), 0.296 in cases (n=437),
and 0.221 in controls (n=436; odds ratio [OR]=1.48; confidence interval [CI]: 1.19–1.85; p=0.0003). The significant
association is retained following multivariate analysis with adjustment for age, smoking status, Complement Factor H
(CFH), Age-Related Maculopathy Susceptibility 2 (ARMS2), Complement Component 2 (CC2), and Complement Factor
B (CFB; OR=1.45; CI: 1.10–1.91; p=0.009). No evidence to support an interaction between any of the covariates within
the regression model was found. The area under the receiver operator characteristic curve calculated for the fully adjusted
model, including all variables, was 0.86 for late AMD.
Conclusions: Our study confirmed the association between Complement Component 3 (C3) and late-stage AMD. There
was no evidence for an interaction with environmental exposures, nor did we find data to support a gene–gene effect.
Age-related  macular  degeneration  (AMD,  MIM
603075)  is  a  degenerative  retinal  disease  that  causes
progressive impairment of the central vision and is the leading
cause of irreversible severe vision loss in Caucasians over the
age of 50 [1]. AMD begins with drusen formation and, in some
cases, degenerative changes at the level of the retinal pigment
epithelium  (RPE),  often  referred  to  as  early  AMD,  that
primarily affects the macula and can progress to the visually
disabling late phenotypes of geographic atrophy (GA) and/or
neovascular  AMD.  Susceptibility  to  AMD  is  complex,
involving  genetic,  lifestyle,  and  environmental  factors,
although  the  specifics  of  the  etiology  remain,  in  part,
unresolved. Advances in our understanding of the genetic
basis of the disease etiology have identified risk and protective
haplotypes in several genes associated with the complement
pathway  and  chronic  inflammation,  such  as  Complement
Factor H (CFH) [2-6], Complement Component 2 (CC2)/
Complement  Factor  B  (CFB)  [7,8],  and  Complement
Component  3  (C3)  [9-11].  A  dysfunctional  complement
pathway has been proposed to accentuate retinal cell damage
with increased formation of drusen deposits, atrophy, and cell
Correspondence  to:  Gareth  J.  McKay,  Centre  for  Vision  and
Vascular  Sciences,  Royal  Victoria  Hospital,  Grosvenor  Road,
Belfast, Northern Ireland, BT12 6BA; Phone: 44 (0)2890 632716;
FAX: 44(0)2890 632699; email: g.j.mckay@qub.ac.uk
degeneration  [12]  and  progression  to  choroidal
neovascularization [5]. A non-synonymous single nucleotide
polymorphism (SNP), rs2230199 (R102G), which causes an
amino acid change from arginine to glycine in C3, has been
most  commonly  associated  with  late-stage  AMD  in  other
studies, primarily due to the functional nature of this variant,
which differentiates between the electrophoretic allotypes of
C3.  As  high  linkage  disequilibrium  (LD)  exists  between
rs2230199  and  rs1047286  (P314L),  the  latter  cannot  be
excluded as a functional variant on the basis of a genetic signal
[11].
Beyond  the  complement  pathway,  the  Age  Related
Maculopathy Susceptibility 2 (ARMS2) locus at chromosome
10q26  has  been  implicated  as  the  other  major  genetic
contributor to the AMD disease process [13-16]. Although
discussion continues regarding the source of the genetic effect
observed at this locus due to high LD within the region, data
have  been  reported  supporting  mitochondrial  involvement
through  interaction  with  the  translocase  of  outer
mitochondrial membrane proteins and co-localization to the
mitochondrial-rich  ellipsoid  region  of  the  photoreceptors
[17,18]. Mitochondrial dysfunction and resultant increased
oxidative stress have been implicated as a component of AMD
disease  etiology,  with  reports  of  increased  mitochondrial
damage in the neural retina and RPE with aging, particularly
in  AMD.  Variation  within  the  mitochondrial  genome  at
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194NADH  ubiquinone  oxidoreductase  chain  2  (MTND2
A4917G) has been reported to confer increased risk associated
with AMD [19,20] and as such would provide an excellent
biologic  candidate  of  functional  significance,  although
subsequent replication and validation in independent cohorts
is necessary. Here, we assess the effect of the C3 functional
variant rs2230199 independent of CFH, ARMS2, CC2, CFB,
age, and smoking status in a Northern Irish cohort; we check
for potential gene–gene or gene–environment interactions,
and we use the area under the receiver operator characteristic
(ROC) curve to quantify the predictive ability of a logistic
regression  model,  incorporating  both  genetic  and
environmental risk factors.
METHODS
Study participants: Patients with end-stage AMD (n=437;
average  age=77.6  years;  39.1%  male),  either  GA  or
neovascular  in  at  least  one  eye  were  recruited
opportunistically between June 2002 and September 2006
from ophthalmology clinics in the Royal Victoria Hospital,
Belfast, UK, which is the regional referral center for Northern
Ireland. DNA was available from an age-matched control
group (n=436; average age=74.9 years; 38.5% male) recruited
through random sampling of older adults (aged 65 years and
above) resident in Northern Ireland and who consented to
stereoscopic digital fundus photography and DNA analysis to
ascertain disease status. Fundi of control participants were
either free of any drusen or had fewer than five hard drusen
of diameter less than 63 µm and absence of focal pigmentary
irregularities,  such  as  hyperpigmentation  or
hypopigmentation, with image grading undertaken by trained
reading  center  staff  using  the  Wisconsin  Age-related
Maculopathy Grading System [21]. All participants were from
Northern Ireland and described themselves as of European
descent.  An  additional  control  sample  (n=485)  obtained
through  random  sampling  of  the  population  from  across
Northern Ireland in 2006 was used to assess allele frequencies
only but had not been assessed for AMD disease status.
Clinical  assessment  of  cases:  Participants  recruited  from
ophthalmology clinics had a confirmed diagnosis of late AMD
made  following  clinical  examination  and  fluorescein
angiography  [21].  In  32  participants,  the  diagnosis  was
advanced atrophic AMD, i.e., geographic atrophy, and 405
participants were diagnosed with exudative AMD. These late-
stage manifestations were present in at least one eye of each
participant.  Cases  with  macular  pathology  due  to  other
primary causes that mimic neovascular AMD, such as myopic
degeneration,  adult  vitelliform,  central  serous  retinopathy,
diabetic  retinopathy,  or  idiopathic  macular  telangiectasia,
were excluded. Those with lens opacities sufficient to obscure
retinal  detail  were  also  excluded.  A  history  of  cigarette
smoking was ascertained at the time of examination, and the
questionnaire  used  had  been  previously  validated  in  the
Whitehall study [22], with participants classified as never
smokers, ex-smokers or current smokers.
Informed written consent was obtained from all subjects
involved. The study was approved by the Research Ethics
Committee of the Queen's University of Belfast and the Office
for Research Ethics Committee, Lisburn, Northern Ireland
and conformed to the tenets of the Declaration of Helsinki.
Genotyping of AMD susceptibility loci: DNA was extracted
from peripheral blood leukocytes or frozen buffy coat samples
using  standard  protocols  in  accordance  with  the
manufacturers’  instructions  (Promega  Wizard®  Genomic
DNA Extraction Kit, Southampton, UK). Genotyping was
undertaken  by  multiplex  PCR  and  primer  extension
methodology using standard manufacturer’s protocols (ABI
Snapshot,  ABI,  Warrington,  UK)  using  custom-designed
primer and probe sequences (Table 1) to ascertain the genetic
data  for  rs1061170,  rs800292,  rs419137,  rs6677604,
rs2284664, and rs3753396 in CFH; rs10490924 in ARMS2;
rs9332739 in CC2; rs641153 in CFB; and rs2230199 in C3.
Statistical analysis: All SNPs were verified, validated, and
assessed for Hardy–Weinberg equilibrium (HWE) separately
in cases and controls, using a χ2 goodness-of-fit test. Allele
frequencies for the SNPs being tested were compared in cases
and  controls  by  the  Pearson's  χ2  test  of  association.  The
assessment of associations of genetic markers with AMD risk
and interactions between genetic markers and between genetic
markers and smoking were obtained using likelihood ratio χ2
tests in a logistic regression model. Age was included in the
model as a continuous variable. Tests for trend for the number
of  risk  alleles  for  each  genetic  variant  (0,  1,  or  2)  were
calculated. Initially only rs2230199 was fitted in the model
and additional covariates were then added to adjust for their
possible confounding effect. CFH haplotypes were entered
into  the  logistic  regression  model  as  a  count  (0,  1,  or  2)
depending  on  the  number  of  copies  of  the  haplotype  an
individual carried. The lowest risk haplotype was omitted
from the model to avoid collinearity problems so that odds
ratios (ORs) were measured relative to homozygote carriers
of this haplotype. For our final risk analysis, the number of
copies carried for rs10490924, rs9332739, and rs641153 were
coded 0, 1, or 2. Tests for interactions between each of the
genotypes and between genotypes and smoking were used to
check for effect modification. The fitted logistic model was
used to order individuals in terms of their predicted AMD risk
dependent  on  their  rs2230199,  CFH,  rs10490924,
rs9332739, and rs641153 genotypes and their smoking status.
A value for the area under the ROC curve, also known as
the C statistic, was evaluated by using only phenotypes from
either end of the severity spectrum, i.e., those with symptoms
of end-stage disease only and those with no features of early
AMD  (namely  pigmentary  irregularities  or  soft  drusen
deposits less than 63 μm). A method to compare the area under
two ROC curves derived from paired measurements was used
Molecular Vision 2010; 16:194-199 <http://www.molvis.org/molvis/v16/a24> © 2010 Molecular Vision
195to assess the value of adding extra variables to the prediction
equation [23].
RESULTS
Univariate analysis: Genomic SNP rs2230199 was assessed
by a χ2 test and was found to be in HWE in both cases and
controls. ORs, confidence intervals (CI), and associated p
values are shown in Table 2. A minor allele frequency of 0.248
was  recorded  for  rs2230199  in  the  general  population
(n=485), and a frequency of 0.296 in cases (n=437) and 0.221
in  controls  (n=436;  OR=1.48;  CI:  1.19–1.85;  p=0.0003),
similar to reports from previous studies [9-11].
Multivariate analysis: The significant effect associated with
rs2230199 was maintained after adjustment for the effects of
age, cigarette smoking status, and carriage of the adverse
alleles of CFH, ARMS2, and CC2/CFB (Table 3: OR=1.45;
CI=1.09–1.91; p=0.009).
Receiver operator characteristic curves: An ROC curve for
cases versus controls with the covariates CFH, ARMS2, CC2,
CFB, C3, smoking status, and age fitted in the regression
model is presented in Figure 1. The area under the ROC curve
that was generated from the model using all covariates was
0.860 (95% CI: 0.834, 0.885; p<0.001), which showed a non-
significant (p=0.22) reduction to 0.857 (95% CI: 0.831, 0.883;
p<0.001) upon removal of C3.
Potential  gene–gene  and  gene–environment  interactions:
Potential gene–gene and gene–environment interactions were
assessed using logistic regression for all the combinations of
C3 and the other parameters recorded within the full model,
such as CFH, ARMS2, CC2, CFB, smoking status, and age.
There was no evidence to support any interaction between the
parameters measured.
TABLE 1. SNAPSHOT PCR PRIMER AND PROBE SEQUENCES
SNP Gene Primer and probe sequence (5′-3′)
rs10490924 ARMS2 F: TTATGTCCCTGTACCCTACATGC
R: AGGAGAGAAGAAGGCTGGTAAGC
Probe: TCACACTCCATGATCCCAGCT
rs419137 CFH F: CAGCTATACCACTGATGTAGAGG
R: CCTACTTACTACTCTCCCATAGG
Probe: GACTGACTGACCACCAACCCTGCAGCACATT
rs6677604 CFH F: ACCAGAGCAGATACAGCAAAAGG
R: AAGCACAATACCTCCACAGTAGC
Probe: ACCCCCCCCAGTTGCCCTGAGAAAATGCGAG
rs2284664 CFH F: GTCATCCATCAAGTGCTACAACC
R: CAGTGGAAGTATGTGCCCTAAGC
Probe: CATCATCATCATAGAAAAATACCAGTCTCCATAGATC
rs3753396 CFH F: CACCTCCTGAACTCCTCAATGG
R: ACTGGTAAAGTTGTCCACTCTCC
Probe: AGACAGACAGACAGACATTTGTCCACTCTCCATCAACACA
rs1061170 CFH F: TTTATCATTGTTATGGTCCTTAGG
R: AGTGTACTTACTGACACGGATGC
Probe: GGACGGACGGACGGACGGACTCCCTGTACAAACTTTCTTCCAT
rs800292 CFH F: GGATTAAGAGCAACCCATTCTCC
R: CTGACCAAACATATCCAGAAGGC
Probe: AAAAAAAAAAACCCCCCCCCCCCCCTGGATATAGATCTCTTGGAAAT
rs9332739 CC2 F: GCGTTGCCATTATCACCTTTGC
R: CCTCTCTCATCACCATCACGTGA
Probe: CCCAAAAACATTTTCCAGGCTGCTGATCAC
rs641153 CFB F: AGCAAGCCAGGACACACCATCC
R: GGAGCCGCCTTTGATCTCTACC
Probe: CCCCCCCCAAAAAACAGAGAGCAGGATCCCTGGGGC
rs2230199 C3 F: CAGGGAGTTCAAGTCAGAAAAGG
R: TCTTGTCTGTCTGTCTGGATGAAGAGG
Probe: CCCCCCCCCCCCCCCCCCCCCCCCCCCGGCCTGCACGGTCACGAACTTGTTGC
TABLE 2. GENOTYPE AND ALLELE FREQUENCIES, ODDS RATIOS, CONFIDENCE INTERVALS (95%) AND P-VALUES FOR RS2230199 IN 437
CASES OF AMD AND 436 CONTROLS.
Genotype Cases n (%) Controls n (%) Odds ratio (95%CI) p value
CC 220 (50.3) 270 (61.9) 1.00 (reference)
CG 175 (40.0) 139 (31.9) 1.55 (1.15–2.08) 0.003
GG 42 (9.7) 27 (6.2) 1.91 (1.11–3.30) 0.013
C allele 615 (70.4) 679 (77.9) 1.00 (reference)
G allele 259 (29.6) 193 (22.1) 1.48 (1.19–1.85) 0.0003
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The polymorphic variation measured for the non-synonymous
SNP rs2230199 in C3 shows significant association with late
AMD  in  the  Northern  Irish  population  and  supports  the
previously noted dose effect with an increased risk of 1.55 for
heterozygotes  (CI:  1.15–2.08;  p=0.003)  and  1.91  for
homozygotes (CI: 1.11–3.30; p=0.013) [9-11]. The OR per
allele  copy  decreases  slightly  from  the  univariate  value
calculated following adjustment through regression analysis
for the following covariates: CFH, ARMS2, CC2, CFB, age,
and smoking (OR=1.45; CI: 1.10–1.91; p=0.009). The minor
allele frequency of rs2230199 ascertained from the general
population sample (n=485) approximates at 0.25.
Considerable  LD  exists  across  this  region,  with  the
majority of investigations reporting the association observed
at  this  locus  on  the  basis  of  the  genotype  at  rs2230199
[9-11]. With evidence supporting a biologic functional effect
through the formation of two common allotypes of C3 (C3F
[fast]  and  C3S  [slow]),  primarily  due  to  variation  in  the
electrophoretic mobility, the rationale for targeting this SNP
for association studies is strong [24]. However, Park et al.
[11] presented data supporting extensive LD within the region
and  suggested  that  until  functional  data  are  produced
supporting rs2230199 as the causal variant in AMD disease
etiology, it is important to consider the potential role of the
non-synonymous SNP rs1047286 (P314L), which is in high
LD  with  rs2230199,  or  indeed  the  potential  role  of  any
additional and as yet undetermined variants that may also be
in complete LD.
Inclusion of rs2230199 as a variable has helped refine our
AMD disease prediction model, providing an area under the
Figure 1. Sensitivities and specificities for a variety of risk score
cutoffs and area under the receiver operator characteristic (ROC)
curve for prediction of age-related macular degeneration. The area
under the ROC curve was 0.860 (95% confidence interval [CI]:
0.834–0.885; p<0.001) for cases versus controls with the covariates
CFH, ARMS2, CC2, CFB, C3, smoking status, and age fitted in the
regression model (solid line). The area under the ROC curve showed
a non-significant reduction (dotted line; p=0.22) to 0.857 (95% CI:
0.831,  0.883;  p<0.001)  upon  removal  of  C3.  The  dashed  line
represents a reference area of 0.50.
TABLE 3. ESTIMATES OF AMD RISK FROM A LOGISTIC REGRESSION MODEL WITH TERMS FOR SMOKING, CFH HAPLOTYPE [6], GENOTYPE AT
ARMS2 A69S (RS10490924) AND THE RISK ASSOCIATED WITH THE CC2/CFB REGION [8].
Risks associated with smoking are relative to never smokers. CFH   haplotypes (1–4; haplotypes 1 and 2 increase risk and are in
complete LD with the C risk allele at Y402H while 3 and 4 are non-risk and in complete LD with the T allele at Y402H) are
measured against haplotype 5 (the most protective haplotype, which is in complete LD with the deletion at CFHR-3 ) [6].
ARMS2   is  measured  on  the  heterozygosity  or  homozygosity  of  the  A69S  risk  allele  (rs10490924 ). rs641153   (CFB ),
rs9332739 (CC2 ) and  rs2230199 (C3) were coded as 0, 1 or 2 depending on the number of copies of the minor allele present.
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Regression term OR 95% C.I. Significance
Ex-smoker versus never smoker 2.34 1.59 3.5 <0.001
Current smoker versus never smoker 5.04 2.96 8.58 <0.001
Number of CFH haplotype 1 3.66 2.24 5.98 <0.001
Number of CFH haplotype 2 4.5 2.85 7.09 <0.001
Number of CFH haplotype 3 2.95 1.8 4.81 <0.001
Number of CFH haplotype 4 1.68 1.01 2.81 0.047
ARMS2 A69S heterozygous 3.64 2.47 5.36 <0.001
ARMS2 A69S homozygous 25.3 13.6 47.2 <0.001
rs641153 (CFB) 0.3 0.18 0.5 <0.001
rs9332739 (CC2) 0.55 0.3 1.01 0.056
rs2230199 (C3) 1.45 1.1 1.91 0.009
Age/year 1.1 1.08 1.13 <0.001ROC curve of 0.860 (Figure 1). Seddon et al. [25] reported an
ROC curve of 0.831 in a longitudinal study of progression to
advanced AMD, using a model incorporating information on
the  genetic  loci  rs1061170  and  rs1410996  in
CFH;rs19490924 in ARMS2;rs9332739 in CC2;rs641153 in
CFB; and rs2230199 in C3 in addition to the response to
therapeutic supplementation. Our ROC area was comparable
to that of Seddon et al. [25], despite the cross-sectional nature
of our study. The similarity of the values determined from this
study to that reported by Seddon et al. [25] may be due to the
homogeneity of our sample in terms of the late-stage disease
phenotype,  which  could  have  contributed  to  an  improved
ROC area. Also, we used an informative representation of the
CFH locus identifying five haplotypes [6] as opposed to the
binary format of the Y402H locus, which is used in most
investigations. Although Seddon et al. [25] used two SNPs,
offering improved power over Y402H alone, we contend that
there is merit in using the haplotypic structure of this locus,
which improved the ROC statistic [6]. This haplotype is based
upon  several  SNPs  from  this  region,  which  enable  the
differentiation of five haplotypes, including the deletion at the
CFHR1–3 locus. It was interesting to note that addition of
rs2230199 within our regression model did not significantly
improve the area under the ROC curve, with only a moderate
increase from 0.857 to 0.860. Evaluation of risk prediction
models requires model performance measures, such as the
popular ROC metric [23]. Its probabilistic interpretation is
based upon the ability of the models’ predicted probabilities
to correctly discriminate between randomly selected diseased
and nondiseased subjects. However, it is known that the area
under  the  ROC  curve  often  shows  only  small  and
nonsignificant improvements, even for a predictor variable
that makes a significant independent contribution in a logistic
regression analysis. More recently, alternative methods for
evaluating  the  usefulness  of  a  new  marker  have  been
proposed, such as event-specific reclassification tables and
integrated  (average)  sensitivity,  although  these
methodologies are more useful in cohort than case-control
studies [26].
In conclusion, the C3 locus has a small but significant
role  in  the  etiology  of  the  disease  process  of  AMD  in
comparison  to  the  other  established  genetic  risk  factors.
Smoking and the genetic risk factors were found to exert an
independent effect in this cohort study. While this conclusion
supports  the  findings  of  other  independent  investigations,
reports have been published supporting gene–gene or gene–
environment  interactions  in  AMD.  Perhaps  it  would  be
appropriate to exercise caution in defining interaction on the
basis of single studies but implementation of replication in
independent data sets in a manner similar to that required for
purely  genetic  association  studies  would  provide  a  more
robust measure.
Our findings add to the literature on calculating AMD risk
and could, in time, facilitate earlier practical intervention for
those at risk, with either lifestyle modification strategies or
preclinical  therapeutic  intervention  when  these  become
available.  These  models  will  also  enable  us  to  identify
predicted high-risk individuals who are aged and have not
progressed  to  a  severe  disease  phenotype  or,  conversely,
individuals with low predicted risk and disease, for inclusion
within future studies for elucidating novel risk factors that
contribute to the AMD disease process.
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